Cyclophosphamide and Alemtuzumab In Lymphoma

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byAnn LaCasce, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Dana-Farber Cancer Institute

No Placebo Group

Trial Summary

What is the purpose of this trial?

This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment. The names of the study interventions involved in this study are: * Cyclophosphamide * Alemtuzumab

Research Team

Ann LaCasce, MD

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

Inclusion Criteria

Participants must have histologically confirmed non-Hodgkin lymphoma and be considered ineligible for standard curative therapeutic options, including high dose chemotherapy with autologous stem cell rescue.

High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements (DHL)

DLBCL or high-grade B-cell lymphoma NOS or B-cell lymphoma unclassifiable with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma with MYC and BCL2 protein over-expression by immunohistochemical (IHC) staining as defined by MYC expression in ≥ 40% of cells and BCL2 positivity ≥ 50% (DOL)

See 7 more

Treatment Details

Interventions

Alemtuzumab (Monoclonal Antibodies)
Cyclophosphamide (Alkylating agents)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Cyclophosphamide and AlemtuzumabExperimental Treatment2 Interventions

After the screening procedures confirm participation in the research study: The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have CD52 positive aggressive lymphoma. Not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated. * Cyclophosphamide * Alemtuzumab